Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Introduction/PurposeRelacorilant is a selective glucocorticoid receptor modulator (SGRM) with no progesterone receptor activity. We evaluated the efficacy and safety of relacorilant in patients with endogenous Cushing syndrome (CS).Materials and MethodsA single-arm, open-label, phase 2, dose-finding...

Full description

Bibliographic Details
Main Authors: Rosario Pivonello, Irina Bancos, Richard A. Feelders, Atil Y. Kargi, Janice M. Kerr, Murray B. Gordon, Cary N. Mariash, Massimo Terzolo, Noel Ellison, Andreas G. Moraitis
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Endocrinology
Subjects:
clinical trial
cortisol
Cushing syndrome
glucocorticoid
hypercortisolism
hyperglycemia
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.662865/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.662865/full

Similar Items